| Type | Title | Date Released | |
|---|---|---|---|
8-K | Quoin Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Updates | ||
10-Q | Form 10-Q | ||
EFFECT | Form EFFECT | ||
8-K | Quoin Pharmaceuticals Enters into At-The-Market Sales Agreement with Leerink Partners | ||
424B5 | November 2026 ATM | Offering amount: $11,000,000 | Bank: Leerink Partners LLC | ||
424B5 | OFFERING - OTHER | Offering amount: $150,000,000 | ||
S-3 | October 2026 SHELF | Float: 161,980,105 EFFECTIVE, DATED 2026-11-04 | ||
4/A | LANGER DENNIS (Reporting) | ||
8-K | Peer-Reviewed Case Report Shows QRX003 Cleared Pediatric Netherton Syndrome Patient’s Skin and Eliminated Itch for 21 Months | ||
8-K | Quoin Pharmaceuticals Receives EMA Orphan Drug Designation for QRX003 in Peeling Skin Syndrome | ||
SCHEDULE 13G/A | Ikarian Capital, LLC (Filed by) | ||
DEF 14A | Form DEF 14A |
